Literature DB >> 21291474

Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors.

Yasuo Uchida1, Sumio Ohtsuki, Yuki Katsukura, Chiemi Ikeda, Takashi Suzuki, Junichi Kamiie, Tetsuya Terasaki.   

Abstract

We have obtained, for the first time, a quantitative protein expression profile of membrane transporters and receptors in human brain microvessels, that is, the blood-brain barrier (BBB). Brain microvessels were isolated from brain cortexes of seven males (16-77 years old) and protein expression of 114 membrane proteins was determined by means of a liquid chromatography-tandem mass spectrometric quantification method using recently established in-silico peptide selection criteria. Among drug transporters, breast cancer resistance protein showed the most abundant protein expression (8.14 fmol/μg protein), and its expression level was 1.85-fold greater in humans than in mice. By contrast, the expression level of P-glycoprotein in humans (6.06 fmol/μg protein) was 2.33-fold smaller than that of mdr1a in mice. The organic anion transporters reported in rodent BBB, that is, multidrug resistance-associated protein, organic anion transporter and organic anion-transporting polypeptide family members, were under limit of quantification in humans, except multidrug resistance-associated protein 4 (0.195 fmol/μg protein). Among detected transporters and receptors for endogenous substances, the glucose transporter 1 level was similar to that of mouse, while the L-type amino acid transporter 1 level was fivefold smaller than that of mouse. These findings should be useful for understanding human BBB function and its differences from that in mouse.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21291474     DOI: 10.1111/j.1471-4159.2011.07208.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  233 in total

1.  Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.

Authors:  M Bauer; M Zeitlinger; R Karch; P Matzneller; J Stanek; W Jäger; M Böhmdorfer; W Wadsak; M Mitterhauser; J P Bankstahl; W Löscher; M Koepp; C Kuntner; M Müller; Oliver Langer
Journal:  Clin Pharmacol Ther       Date:  2011-12-14       Impact factor: 6.875

2.  Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.

Authors:  Sagar Agarwal; Yasuo Uchida; Rajendar K Mittapalli; Ramola Sane; Tetsuya Terasaki; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-03-08       Impact factor: 3.922

Review 3.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

4.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 5.  In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use.

Authors:  Hans C Helms; N Joan Abbott; Malgorzata Burek; Romeo Cecchelli; Pierre-Olivier Couraud; Maria A Deli; Carola Förster; Hans J Galla; Ignacio A Romero; Eric V Shusta; Matthew J Stebbins; Elodie Vandenhaute; Babette Weksler; Birger Brodin
Journal:  J Cereb Blood Flow Metab       Date:  2016-02-11       Impact factor: 6.200

6.  The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.

Authors:  Joao N Dos Santos Pereira; Sina Tadjerpisheh; Manar Abu Abed; Ali R Saadatmand; Babette Weksler; Ignacio A Romero; Pierre-Olivier Couraud; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  AAPS J       Date:  2014-08-26       Impact factor: 4.009

7.  Cerebrovascular Angiogenic Reprogramming upon LRP1 Repression: Impact on Sphingosine-1-Phosphate-Mediated Signaling in Brain Endothelial Cell Chemotactism.

Authors:  Amélie Vézina; Cyndia Charfi; Alain Zgheib; Borhane Annabi
Journal:  Mol Neurobiol       Date:  2017-05-17       Impact factor: 5.590

8.  A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.

Authors:  Jana Portnow; Behnam Badie; Susan Markel; An Liu; Massimo D'Apuzzo; Paul Frankel; Rahul Jandial; Timothy W Synold
Journal:  Eur J Cancer       Date:  2013-02-04       Impact factor: 9.162

9.  Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection.

Authors:  Bruna Dos Santos Rodrigues; Hiroshi Oue; Amrita Banerjee; Takahisa Kanekiyo; Jagdish Singh
Journal:  J Control Release       Date:  2018-07-31       Impact factor: 9.776

10.  An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.

Authors:  Hans Christian Helms; Maria Hersom; Louise Borella Kuhlmann; Lasina Badolo; Carsten Uhd Nielsen; Birger Brodin
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.